Nanoengineered microneedle arrays for enhanced delivery of long-acting HIV medicines

纳米工程微针阵列可增强长效艾滋病毒药物的输送

• 批准号: EP/S028919/1
• 负责人: Ryan Donnelly
• 金额: $ 139.58万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FS028919%2F1
• 关键词: Nanoengineered; microneedle; arrays; enhanced; delivery

HIV/AIDS remains a major public health threat, with approximately 36.7 million people worldwide infected. In 2016, HIV-related diseases claimed almost 1 million lives globally, with 1.8 million people being newly infected that same year. Around 20.9 million people were accessing antiretroviral therapy in 2017, constituting ~54% of adults and ~43% of children infected with the virus. . In 2016, 42% of diagnoses happened at a late stage of infection and awareness and knowledge around HIV is dropping in the UK, emphasising the value of preventative treatments. Current methods of delivering medicines for treatment and prevention of HIV are far from optimal, necessitating multiple daily tablets or painful monthly injections.In this project we will design and test a novel type of transdermal patch that has hundreds of tiny projections on its surface. Upon painless skin application, these "microneedles" will dissolve and leave behind microscopic particles of medicine for treatment or prevention of HIV. These particles will dissolve over weeks or months to deliver therapeutic doses of the medicine. We will use state-of-the art expertise, including high power computational models to design and predict the behaviour of the medicine particles, speeding up product design and informing laboratory experiments.The technology developed here is unique and could potentially revolutionise prevention and treatment of HIV infection. It offers the opportunity for dramatically improved treatment, with potential benefits for both patients and the NHS. Ultimately, commercialisation of the technology will be the primary route by which UK industry, the NHS and patients will derive benefits. In order to attract potential industrial or venture-funding partners, it is vitally important to demonstrate proof of concept for this technology, which is the over-arching aim of the present proposal.

艾滋病毒/艾滋病仍然是一个主要的公共卫生威胁，全世界大约有3670万人感染。 2016年，与艾滋病毒相关的疾病在全球享有近100万人的生命，同年有180万人被​​新近感染。 2017年，大约有2090万人正在接受抗逆转录病毒疗法，占成年人的约54％，受病毒感染的儿童中约有43％。 。 2016年，42％的诊断发生在英国的感染后期，围绕艾滋病毒的意识和知识正在下降，强调了预防治疗的价值。当前提供用于治疗和预防艾滋病毒的药物的方法远非最佳，需要每日片剂或每月注射痛苦。在此项目中，我们将设计和测试一种新型的透皮贴片，在其表面上具有数百个微小的预测。涂抹无痛的皮肤后，这些“微针”将溶解并留下微观的药物颗粒，以治疗或预防HIV。这些颗粒将在数周或几个月内溶解以提供治疗剂量的药物。我们将使用最先进的专业知识，包括高功率计算模型来设计和预测药物颗粒的行为，加快产品设计并为实验室实验提供通知。这里开发的技术是独一无二的，可能会彻底改变预防和治疗HIV感染。它为大大改善治疗提供了机会，对患者和NHS都有潜在的好处。最终，该技术的商业化将是英国行业，NHS和患者将获得收益的主要途径。为了吸引潜在的工业或风险投资合作伙伴，证明这项技术的概念证明至关重要，这是本提案的整理目标。

项目成果

Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis

• DOI: 10.1016/j.matdes.2022.111416
• 发表时间: 2022-11-24
• 期刊: MATERIALS & DESIGN
• 影响因子: 8.4
• 作者: Paredes, Alejandro J.;Permana, Andi Dian;Donnelly, Ryan F.
• 通讯作者: Donnelly, Ryan F.

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.

• DOI: 10.3390/pharmaceutics15122709
• 发表时间: 2023-11-30
• 期刊: Pharmaceutics
• 影响因子: 5.4
• 作者: Kinvig H;Rajoli RKR;Pertinez H;Vora LK;Volpe-Zanutto F;Donnelly RF;Rannard S;Flexner C;Siccardi M;Owen A
• 通讯作者: Owen A

Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.

• DOI: 10.1007/s11095-022-03408-6
• 发表时间: 2023-07
• 期刊: Pharmaceutical research
• 影响因子: 3.7
• 作者: Moffatt K;Tekko IA;Vora L;Volpe-Zanutto F;Hutton ARJ;Mistilis J;Jarrahian C;Akhavein N;Weber AD;McCarthy HO;Donnelly RF
• 通讯作者: Donnelly RF

The promise of microneedle technologies for drug delivery.

• DOI: 10.1007/s13346-023-01430-8
• 发表时间: 2023-10
• 期刊: Drug delivery and translational research
• 影响因子: 5.4
• 作者: R. Donnelly;M. Prausnitz

Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches.

• DOI: 10.1016/j.mtbio.2022.100217
• 发表时间: 2022-01
• 期刊: Materials today. Bio
• 作者: Paredes AJ;Volpe-Zanutto F;Vora LK;Tekko IA;Permana AD;Picco CJ;McCarthy HO;Donnelly RF
• 通讯作者: Donnelly RF